Skip to content

Trial Summary

A phase-3, randomized, open-label study to evaluate the efficacy and safety of olaparib alone or in combination with bevacizumab compared to bevacizumab with 5-FU in participants with unresectable or metastatic colorectal cancer.

Acronym:

LYNK-003

ACTRN/NCT /ethics:

NCT04456699

Scientific title:

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer

Sponsor / Cooperative group:

Merck Sharp & Dohme Corp.

Trial & Patient Characteristics

Cancer TypeBowel & Colon
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2020-08-19
Anticipated End Date2027-01-22

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorProfessor Tim Price
Recruitment StatusRecruiting